clonoSEQ Receives FDA Clearance for MRD Assessment in CLL

On August 5, 2020, clonoSEQ® (Adaptive Biotechnologies®), a next-generation sequencing assay that detects and monitors measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL), received U.S. Food and Drug Administration (FDA) clearance for MRD assessment in blood and bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is covered by Medicare for these indications.

Read the Press Release. For prescribing information and test limitations view the clonoSEQ Technical Summary.

On August 5, 2020, clonoSEQ® (Adaptive Biotechnologies®), a next-generation sequencing assay that detects and monitors measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL), received U.S. Food and Drug Administration (FDA) clearance for MRD assessment in blood and bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is covered by Medicare for these indications.

Read the Press Release. For prescribing information and test limitations view the clonoSEQ Technical Summary.